



10/522265  
PCT/GB03/003187  
Rec'd PCT/PTO 25 JAN 2005

INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

REC'D 18 AUG 2003

WIPO


PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated

6 August 2003

**Best Available Copy**

Patents Form 1/77

The  
Patent  
Office

1/77

Patent (Rule 10) 1977

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)

The Patent Office  
Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference 96.78832

2. Patent application number  
(The Patent Office will fill in this part)

25 JUL 2002

0217285.6

3. Full name, address and postcode of the  
or of each applicant (underline all surnames)

Cambridge Consultants Limited  
Science Park  
Milton Road  
Cambridge, Cambs  
CB4 0DW

Patents ADP number (if you know it) 00361618001

If the applicant is a corporate body, give  
country/state of incorporation

United Kingdom

4. Title of the invention

Syringes

5. Name of your agent (if you have one)

Frank B. Dehn & Co.

"Address for service" in the United Kingdom  
to which all correspondence should be sent  
(including the postcode)

179 Queen Victoria Street  
London  
EC4V 4EL

Patents ADP number (if you know it)

166001

6. If you are declaring priority from one or more  
earlier patent applications, give the country  
and the date of filing of the or of each of these  
earlier applications and (if you know it) the or  
each application number

Country

Priority application number  
(if you know it)

Date of filing  
(day / month / year)

7. If this application is divided or otherwise  
derived from an earlier UK application,  
give the number and the filing date of  
the earlier application

Number of earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right  
to grant of a patent required in support of  
this request? (Answer 'Yes' if:

Yes

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- See note (d))

# Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

0

Description

13

Claim(s)

0

Abstract

0

Drawing(s)

5 + 5

June

10. If you are also filing any of the following, state how many against each item.

Priority documents

0

Translations of priority documents

0

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

0

Request for preliminary examination and search (Patents Form 9/77)

0

Request for substantive examination (Patents Form 10/77)

0

Any other documents (please specify)

No

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date 25 July 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Adrian Samuels  
01273 244200

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s) of the form. Any continuation sheet should be attached to this form.
- If you have answered 'Yes', Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

78832.70

SYRINGES

5 This invention relates to syringes - particularly, although not exclusively, syringes which are suitable for reconstituting lyophilised substances prior to administration.

10 Many drugs and medicaments are routinely supplied in lyophilised form. This has the advantage of significantly extending the shelf life of the drug or medicament, eliminating the need for the drug to be stored under a careful temperature regime or simply permitting storage of a substance which would otherwise quickly break down. Immediately prior to being  
15 required, the lyophilised drug may be reconstituted by mixing it with a suitable diluent.

Conventionally, lyophilised drugs are supplied in glass vials. Glass is used since it is very inert and may therefore safely be used to store a wide variety of  
20 substances. Furthermore it has extremely good barrier properties and therefore permits long term storage without contamination etc.

A diluent is either extracted from another glass vial by a syringe with a needle for piercing the rubber  
25 septum thereof, or is supplied in a pre-filled syringe. The diluent is then injected into the vial containing the drug by using the needle on the syringe to pierce the rubber septum of the drug vial. Once the drug has been reconstituted, the syringe is used to draw the  
30 reconstituted drug out of the vial, ready for injection into a patient.

Clearly the requirement to penetrate a relatively small rubber septum at least once with a needle gives rise to the danger of injury to the user. Furthermore  
35 the addition of diluent to the drug is entirely under the control of the user. One problem this can give rise to is that the diluent can be added too quickly. Too

high a flow rate of diluent onto the drug can cause it to shear excessively. Lyophilised drugs tend to be delicate and some can be damaged by excessive shearing. A high flow rate may also cause the diluent and drug mixture to undergo undesirable foaming.

5 Various arrangements have been proposed for allowing lyophilised drugs to be reconstituted inside a device thereby avoiding some of the potential for injury associated with the conventional method of  
10 reconstitution. Examples of such arrangements are shown in WO 01/26718, WO 96/29106 and EP-A-1038543. However, all of the previous arrangements suffer from some drawbacks.

15 It is an object of the invention to provide an improved way of reconstituting drugs and when viewed from a first aspect the invention provides a two-part syringe comprising two chambers, each chamber having an associated plunger operable to eject fluid therefrom, said plungers being interlinked so as selectively to  
20 prevent movement of one of said plungers in its respective chamber dependent upon the position of the other plunger.

Thus it will be seen in accordance with the present invention that by suitable design of the interlinking  
25 between the two plungers of a two-chamber syringe, the order and extent to which each may be operated can be controlled. By providing a lyophilised drug and diluent respectively in the two chambers, for example, such an arrangement could be used to ensure that diluent  
30 is expelled from its chamber and into the chamber containing the lyophilised drug before the reconstituted drug can be expelled. Furthermore it can be arranged that the drug cannot be injected into a patient until the correct quantity of diluent has been used.

35 Another possible use for an embodiment of the invention might be to ensure that two substances to be administered in conjunction with one another are

administered in the correct order.

By interlinking the two plungers in accordance with the invention it may be ensured that, at each stage of a drug preparation and administration procedure, only the correct plunger may be actuated. This prevents any possible accident or misuse of the device meaning that a minimal amount of instruction in how to operate the syringe is required. This potentially opens up the possibilities for drugs to be administered by non-medical staff or by patients themselves, giving increased convenience to patients and saving costs.

The two plungers could be interlinked by any suitable means. For example one plunger could be arranged to release or set a latch, catch or the like preventing operation of the other. Preferably, however, a cam means is associated with the plungers. In a particularly preferred embodiment each plunger comprises a cam track cooperating with a common cam shuttle member comprising followers for each cam track. Preferably such a cam shuttle is constrained to move within a void extending perpendicularly to the plungers. This void could be defined by a separate member or as an integral part of a housing for the syringe.

There are many different patterns of actuation of the two plungers which the interlinking could be configured to allow. The skilled person can therefore select the required pattern depending upon the application for which the syringe is to be used. In preferred embodiments where the syringe is for use in reconstituting and injecting lyophilised drugs, the interlinking is configured to prevent injection of the drug until it has been reconstituted with diluent.

The two plungers could be made identical in appearance. Preferably however, they are different in appearance - for example one may be larger than the other or, preferably, they are different colours. This allows a user easily to identify which should be

operated at which stage, thereby avoiding frustration or confusion on the part of a user attempting to operate a plunger which is not intended to be operated at that stage and which, therefore, is prevented from doing so.

5       The two chambers could be maintained isolated from one another so that their contents are delivered independently subject to the configuration of the plunger interlink. Preferably however, the syringe is arranged such that the two chambers can be placed  
10       selectively in fluid communication with one another. This allows, for example, reconstitution of a lyophilised drug within one of the chambers. In a preferred embodiment a communicating conduit is provided which is movable into fluid communication with one or  
15       both of the chambers. Most preferably such movement is arranged to breach a seal such as a septum or the like associated with one or both of the chambers. For example, the communicating conduit may comprise one or  
20       two needles for breaching said seal or seals. If two needles are provided, they may be arranged to breach the respective seals or the chambers at the same time. Alternatively, they could be arranged to breach the seals in a predetermined order, e.g. by making one longer than the other.

25       The communicating conduit preferably comprises a tortuous or complex fluid path such that liquid forced therethrough under ordinary manual pressure on one of the plungers is caused to exit the conduit substantially without jetting. Provision of a tortuous path giving a  
30       high pressure drop and low fluid exit speed is especially advantageous in the reconstitution of some lyophilised drugs which can be harmed if foaming or shearing occurs.

35       In particularly preferred embodiments the communicating conduit is provided on a separate support member which is preferably slidable towards or away from the chambers.

By providing the communicating conduit on a separate support member, the transient pathway for the substances can be separated from the part of the apparatus required to provide storage. This allows, in  
5 a preferred embodiment, the superior inertness and barrier properties of glass to be used for the storage section whereas the transient section, which is separated from the storage section during storage and thus is not subject to the same stringent inertness and  
10 barrier requirements, can be made from plastics. This substantially facilitates its manufacture and easily allows the tortuous path mentioned above to be provided. It also allows, if suited to the particular application, needles to be integrally moulded at the ends of the  
15 conduit for breaching seals on the chambers. Alternatively separate e.g. steel needles could be attached to the ends of the conduit for this purpose. Either way, the support member gives another advantage that the user can breach the seals without having to  
20 come into contact with a needle since the needles can effectively be embedded within the structure of the syringe.

Furthermore, by providing a separate sliding support member incorporating the communicating conduit,  
25 fluidly joining the two previously separated chambers is easily achieved whilst allowing the two chambers to be fabricated, filled and, where appropriate, sterilised separately from one another. An example of why this is advantageous is given by the case of an embodiment in  
30 which the two chambers are pre-filled with lyophilised drug and diluent respectively. The diluent chamber and peripheral parts of the device must, in general, be sterilised. However, the sterilisation process can often damage lyophilised drugs. In accordance with the  
35 arrangement described above however, the two chambers may be prepared independently of one another and mounted together only in a final step. This facilitates



production of such devices.

In fact it will be appreciated that the foregoing arrangements are novel and inventive in their own right and thus when viewed from a second aspect the invention provides a syringe for reconstituting a lyophilised substance comprising a first chamber containing or for containing the lyophilised substance and a second chamber containing or for containing a diluent; the first and second chambers being arranged generally adjacent one another; the syringe further comprising a communicating conduit for fluidly connecting the two chambers, said fluid connection means being selectively engageable with the two chambers.

Preferably the conduit is provided on a support member separate from the two chambers. Most preferably the support is such as to be slidable so as to bring the conduit into and out of engagement with the chambers. It is also preferred that the two chambers have respective associated plungers which are interlinked to prevent activation of one depending upon the position of the other in accordance with the first aspect of the invention. Similarly it is also preferred that the conduit has a tortuous configuration as previously described to prevent foaming or shearing of the drug during reconstitution.

Where in the present application the term "plunger" is used, it should be appreciated that the invention is not limited to any particular form of construction and that in fact any suitable means of reducing volume in the chamber and/or expelling the contents therefrom could be substituted.

A preferred embodiment of the invention will now be described, by way of example only, with reference to the accompanying drawings in which:

Figure 1 is a cross-section through a syringe in accordance with the invention in its storage position;

Figure 2 shows the syringe of Figure 1 with the

septums pierced;

Figure 3 shows the syringe after reconstitution of a drug;

5 Figure 4 shows the syringe after purge and injection of the drug; and

Figure 5 shows the syringe after flushing.

Turning firstly to Figure 1, there may be seen a cross-section through a syringe in accordance with the present invention. It may be seen that the syringe  
10 comprises two chambers in the form of glass vials 2,4 each being associated with a respective plunger 6,8. Each plunger 6,8 has a synthetic rubber bung 10,12 attached or over-moulded onto the end of the corresponding plunger. The upper vial 2 is intended in  
15 use to contain a lyophilised drug and thus the plunger bung 10 is designed to provide any necessary barrier properties and/or difference in pressure relative to ambient which might pertain to the required storage of the particular lyophilised drug in question.

20 The lower vial 4 is intended in use to contain a liquid diluent suitable for reconstituting the lyophilised drug in the upper chamber 2. Thus, the bung 12 on the diluent plunger 8 is capable not only of providing a liquid-tight seal, but also of providing a  
25 sufficient barrier against contamination of the sterilised diluent. In this embodiment the plungers 6,8 for the drug and diluent are coloured red and blue respectively for ease of identification but this is by no means essential.

30 At the opposite end of each vial 2,4, is provided a rubber septum 14,16. As with the rubber bungs 10,12, the rubber septums 14,16 provide the required barrier properties for the intended shelf life of the materials in the syringe. The two vials 2,4, are held in a two-  
35 part clam shell outer casing moulding 18 which also protects them from damage. The outer casing 18 incorporates two finger rests 20 which, as is

conventionally known, allow a user to apply thumb pressure to the ends of the plungers 6,8.

5 The front end 18a of the outer moulding defines a pair of apertures 22,24 in alignment with the two  
respective septums 14,16 to provide access to them. The housing front end 18a is covered by a plastics front end  
moulding 26 which is mounted so as to be able to slide axially relative to the syringe housing 18. In the  
10 storage position shown in Figure 1 it is offset towards the left - i.e. at the leftmost end of its travel, when viewed from Figure 1.

The front end moulding 26 has a pair of steel  
needles 28,30 mounted inside which extend into the  
apertures 22,24 respectively in the front face of the  
15 syringe housing 18a. In an alternative embodiment (not shown) the needles can be integrally moulded from the same plastics material as the front cap. The two  
needles 28,30 are fluidly connected at their other ends by a conduit in the form of a narrow bore 32. Although  
20 not visible in the Figure, the narrow bore 32 has a tortuous configuration.

Also in fluid communication with the narrow bore 32  
is the central bore of a nozzle 34 at the front end of  
the frnt end moulding 26. The nozzle 34 will in use be  
25 connected to an administration set such as a line set, cannula or hypodermic needle and thus defines the exit path 36 from the syringe. The nozzle 34 is of standard configuration in order to co-operate with commonly  
available administration sets. A nozzle cap 36 is  
30 provided over the nozzle 34 to maintain sterility of the syringe.

Attached to the rear end of the syringe housing 18  
is another plastics moulding 38, although this could  
equally be integrally formed with the housing. The rear  
35 moulding 38 defines a void in which is provided a cam guiding shuttle 40 which is moveable in within the rear moulding 38 in a direction perpendicular to the plungers

6,8. The shuttle 40 has a pair of integrally moulded cam followers in the form of pins (not visible) which engage respectively in grooves defining cam tracks 42,44 in the shafts of the two plungers 6,8.

5           It will be seen that in Figure 1, the shuttle 40 is in its upper position since the two followers are at the leftmost ends of the cam tracks 42,44. It should further be noted that although the upper cam follower is not prevented from moving down (i.e. towards the main  
10       axis of the syringe) by its cam track 42, it is prevented from doing so by virtue of being integrally formed with the shuttle 40 and therefore the lower cam follower which is prevented from moving in the  
15       aforementioned direction by the lower cam track 44. The result of this is that the plunger 6 cannot be depressed the user is unable to attempt to expel the lyophilised drug from the vial 2. Moreover, by preventing movement of the drug vial plunger 6, a vacuum may be maintained in the drug vial 2 which may be important for certain  
20       drugs.

          During fabrication of the syringe shown in Figure 1, the two clam shells of the front end moulding 26 and the needles 28 are assembled together by e.g. ultrasonic welding. The nozzle cap 36 is then added to this  
25       assembly. The front end assembly is then assembled onto one clam shell half of the syringe outer housing 18 along with the rear end moulding 38 and the shuttle 40.

          The lower glass vial 4 and plunger 8 are fabricated and assembled and then filled with a suitable diluent  
30       before the rubber septum 16 is fitted. The diluent vial assembly is then mounted into the bottom half of the main syringe housing 18 to which the front and rear mouldings 26, 38 were attached. The whole assembly is then passed through a terminal sterilisation process,  
35       known *per se*.

          In a separate part of the fabrication plant, the upper glass vial 2 (with plunger 6) is filled with the

desired liquid drug and then passed through the stages, well known *per se* in the art, necessary to lyophilise the drug and fit the rubber septum 14.

5 The drug vial assembly 2,6,14 is assembled into the lower half of the syringe housing 18 and the upper half of the housing 18 added and secured to complete the assembly. Thus the diluent vial 4 and the rest of the syringe may be sterilised without harming the delicate lyophilised drug which may be prepared in its vial 2 in  
10 the normal way. This makes assembly of the syringe straightforward.

It will be appreciated by those skilled in the art that the syringe as shown in Figure 1 may be stored for a long period of time since the lyophilised drug and the  
15 diluent are completely sealed within the two vials 2,4 respectively. Moreover, lyophilisation of the drug ensures its long term stability. Although the position of the shuttle 40 is not preventing depression of the diluent plunger 44, in practice such depression is  
20 prevented by hydraulic resistance of the diluent in the vial 4 since, as mentioned above, the vial is completely sealed.

When it is desired to use the drug by injecting it, the lyophilised drug must first be reconstituted. The  
25 first step in achieving this is shown in Figure 2. As will be seen from a consideration of Figures 1 and 2, in Figure 2 the front end moulding 26 has been slid onto the front end of the syringe housing 18a. This causes the needles 28,30 to pass through the apertures 22,24 in  
30 the front of the housing 18a and to pierce the septums 14,16. A fluid path between the two vials 2,4 is therefore provided via the two needles 28,30 and the narrow bore 32. It will be noted that the cap 36 is  
35 retained at this stage in order to ensure that the fluid paths 28-34 and the two vials 2,4 are maintained sterile and to ensure that the sole fluid path opened is between the two vials.

Since, in the described embodiment, the lyophilised drug is stored under vacuum in the drug vial 2, when the fluid path is opened as shown in Figure 2, diluent from the diluent vial 4 will automatically be drawn through the narrow bore 32 into the drug vial 2. The reduction in pressure in the diluent vial 4 causes the diluent plunger 8 to move forwards as may be seen in Figure 3. Depending upon the degree of vacuum in the drug vial 2, it may be necessary to apply some manual pressure to the plunger 8 to reach the position shown in Figure 3. In an alternative embodiment (not shown) the drug is not stored under pressure and the configuration of the cam tracks 42,44 is different in order to allow the syringe to be stored with the drug plunger partially depressed and able to move out of the drug vial to accommodate diluent being injected in.

The tortuous narrow bore 32 ensures a high pressure drop across it. This means that under normal manual pressure on the diluent plunger 8, diluent will exit into the drug vial 2 at a dribble - i.e. such a low liquid velocity that jetting does not occur and potentially harmful foaming or shearing are avoided. Mixing of the diluent and the lyophilised drug in the drug vial 2 effects reconstitution of the drug ready for use.

It may further be seen from Figure 3 that the forward movement of the diluent plunger 8 and the downwardly curving shape of the corresponding part of its cam track 44 causes the shuttle 40 to move from its original upper position to the lower position. The upwardly kinked shape of the cam track 44 at this point prevents any further forward movement of the diluent plunger 8. A proportion of the diluent will therefore remain in the diluent vial 4.

It will further be appreciated that since in Figure 3 the shuttle 40 has moved downwards, this will move the cam follower in the cam track 42 of the drug plunger 6

thereby enabling it to be depressed when required. However, this will not be possible until the correct quantity of diluent has been dispersed.

5       Once reconstitution of the drug has taken place,  
the cap 36 on the nozzle 34 may be removed and the  
nozzle 34 attached to a cannula or butterfly introducer  
set. The drug plunger 6 is then actuated a short way to  
purge the system of air as will be well known to the  
user. The user will then typically insert the  
10       hypodermic needle into the patient (which could of  
course be the user themselves), carrying out a vein check  
to ensure that the needle is correctly inserted or not  
in the blood stream as appropriate. The user may then  
depress the drug plunger 6 fully in order to inject the  
15       reconstituted drug into the patient. During this part  
of the operation, the syringe is used exactly as a  
conventional syringe would be.

      The skilled person will appreciate that although  
the fluid path between the vials 2,4 via the narrow bore  
20       32 remains open during the injection procedure, in  
practice the difference in pressure between the narrow  
bore 32 and the exit path through the nozzle 34 will  
ensure that substantially none of the drug is diverted  
into the narrow bore 32 or the diluent vial 4. If  
25       necessary, this can be further ensured by providing the  
diluent bung 12 with barbed-like projections in order to  
increase its resistance to moving back along the vial 4.

      Turning now to the shuttle 40, it will be seen that  
after full actuation of the drug plunger 6, the upward  
30       curve at the end of its cam track 42 causes the shuttle  
40 again to move to its upper position. This permits  
further actuation of the diluent plunger 8 as may be  
appreciated by considering the shape of its cam track  
44.

35       The final step in the procedure is shown in Figure  
5. In this Figure, it may be seen that the diluent  
plunger 6 has also been fully actuated as is permitted

by the upward position of the shuttle 40. This flushes all the internal fluid paths 30,32,34 of any remaining drug using the remainder of the diluent. The only part of the system which will not be flushed is the drug  
5 needle 28, but it will be appreciated by those skilled in the art that the volume of the needle 28 is extremely low and at least an order of magnitude less than the volume of a standard subcutaneous cannula. The difference is even more pronounced when compared with a  
10 butterfly introducer. Thus, it may be ensured that the patient receives substantially all of the intended dose.

It will be seen from the foregoing description that at least a preferred embodiment of the invention provides a two-part syringe which can be used to store  
15 and subsequently reconstitute a lyophilised drug and thereafter inject it into a patient in an entirely conventional manner without the user ever having to come into contact either with the drug or the diluent, or indeed without having manually to pierce the septums  
20 with a needle.

More importantly, however, it will also be seen that the interlinking of the two plungers by the shuttle and respective cam tracks ensures that only the correct plunger may be actuated at the correct time. This makes  
25 administration of the drug by non-medical staff or self-administration by patients a greater possibility.

It will be appreciated by those skilled in the art that the embodiment described above is just one example of the application of the principles of the present  
30 invention and that many variations and modifications are possible within the scope of the invention. For example, the invention is not limited to the reconstitution of lyophilised drugs and indeed  
35 embodiments of the invention may find many different applications where it is desired to ensure the correct sequence of actuation of a pair of syringe plungers.






Figure 1





Figure 2



**Figure 3**





Figure 4



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**